Vitamin K epoxide reductase

From WikiMD's WELLNESSPEDIA

Vitamin K epoxide reductase


Vitamin K epoxide reductase (VKOR) is a key enzyme in the vitamin K cycle, which is crucial for the post-translational modification of certain proteins, mainly involved in the blood coagulation process and bone metabolism. This enzyme catalyzes the reduction of vitamin K 2,3-epoxide to its active form, vitamin K hydroquinone, thereby enabling the carboxylation of glutamate residues on the prothrombin precursors of clotting factors II, VII, IX, and X, as well as proteins C, S, and Z. This carboxylation step is essential for their biological activity.

Function[edit]

VKOR plays a pivotal role in the vitamin K cycle, a critical pathway in the body's ability to form blood clots. The active form of vitamin K, produced by VKOR, is a cofactor for the enzyme gamma-glutamyl carboxylase, which modifies glutamate residues in certain proteins to gamma-carboxyglutamate (Gla). These modifications allow the proteins to bind calcium ions, which is necessary for their activity in the coagulation cascade.

Clinical Significance[edit]

Mutations in the VKORC1 gene, which encodes the VKOR enzyme, can lead to deficiencies in vitamin K-dependent clotting factors, resulting in bleeding disorders. Additionally, VKOR is the target of anticoagulant drugs, such as warfarin. These drugs inhibit the enzyme, preventing the activation of vitamin K and thus the clotting factors, which is useful in the treatment of thromboembolic diseases.

Pharmacology[edit]

Warfarin and other vitamin K antagonists (VKAs) are widely used as anticoagulants. The action of these drugs is monitored by measuring the prothrombin time (PT) and adjusting the dose to maintain the international normalized ratio (INR) within a therapeutic range. Resistance to warfarin, due to mutations in the VKORC1 gene, requires higher doses to achieve the desired anticoagulant effect.

Genetics[edit]

The VKORC1 gene is located on chromosome 16 and consists of three exons. Variants in this gene can affect the enzyme's activity and the individual's response to vitamin K antagonists. Genetic testing can identify these variants to guide the dosing of warfarin and reduce the risk of bleeding or thrombosis.

See Also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.